Stocks-SDGR-Schrodinger Inc/United States

SDGR Schrodinger Inc/United States

24.63 0.35 (1.44%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

Performance

-6.32% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
-
Day’s Range
24.24
-
25.02
52W Range
15.80
-
36.16
Volume (3M)
-
Price-Earnings Ratio
-
Revenue
-

Schrodinger Inc/United States Latest News

View All
Top Discussions
S33k_N_Trad3
Mein Portfolio ist im vergangenen Trading-Tag um 2.51 % gestiegen! Erfahren Sie mehr www.etoro.com/de/people/s33k_n_trad3/portfolio $MATIC $NVS (Novartis ADR) $NESN.ZU (Nestle SA) $SDGR (Schrodinger Inc/United States) $ETC Translate
Like CommentShare
null
.
MarketUpdates
Edited
$SDGR (Schrodinger Inc/United States) Q1 2023 earnings report is expected to be released
3
MAY
REPORTS
Schrodinger Inc/United States Q1 2023 earnings report is expected to be released after market open
Notify me
SDGR
SDGR
Schrodinger Inc/United States
24.63
0.35
(1.44%)
Trade
MarketUpdates
$SDGR (Schrodinger Inc/United States) Q1 2023 earnings report is expected to be released
MarketUpdates
$SDGR (Schrodinger Inc/United States) Q1 2023 earnings report is expected to be released
MarketUpdates
$SDGR (Schrodinger Inc/United States) Q1 2023 earnings report is expected to be released

About Schrodinger Inc/United States

In a valiant attempt to improve the quality of human health, Schrödinger Inc. prides itself on its team of excellent academics, executives, and entrepreneurs. Recognised for their achievements in the biotech industry, Richard Friesner and Bill Goddard III, originally founded Schrödinger Inc. of New York in 1990. Within two years, SDGR successfully sold its software to Brookhaven National Laboratory. Headquartered in New York today, Schrödinger utilises a physics-based computational platform and discovers solutions for predictive modelling, that is, data analysis with a strong focus on the rapid exploration of chemical space. This allows artificial intelligence to explore efficient means of bringing new pharmaceuticals to the world market. With strong pharma partners, Takeda and Sanofi, SDGR is the parent company of Synaptic Science LLC and Faxian Therapeutics LLC. Schrödinger Inc. initiated a Gates & Daniel Shaw backed IPO in February 2020 and the stock traded at $27.22/share. In the following six months, the share price rose by approximately $40.00 a share. This company is in a very competitive Biotechnology (IBB) sector and announced a recent public offering of $4.5m shares of their common stock. For a diverse portfolio chart this stock for its potential. More in-depth research is required into the complexities of this category but it could be a great candidate to buy for swing-trade eToro traders.
787
Employees
New York, New York, US
HQ
1990
Founded
Ramy Farid, PhD
CEO
Show More

Upcoming Earnings

3
MAY
REPORTS
Schrodinger Inc/United States Q1 2023 earnings report is expected to be released after market open

Analyst Forecast

Consensus
Moderate Buy
Price Target
89.00

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
54
Medium
Industry 
Avg. 48 
35
Environment
50
Social
62
Governance

People Also Bought